|
Advisory
Committees
Waivers for Conflicts of Interest
The Food and Drug Administration Amendments Act of 2007 (FDAAA), enacted on September 27, 2007, added a new provision regarding financial conflicts of interest, § 712 of the Federal Food, Drug, and Cosmetic Act (FD&C Act), effective October 1, 2007. Accordingly, for advisory committee meetings after October 1, 2007, FDA is granting waivers under 18 U.S.C. § 208 and § 712 of the FD&C Act, where applicable, when the relevant waiver standards in these statutes are met.
Waivers under 21 U.S.C. § 355(n)(4) were issued before October 1, 2007. This provision was repealed, effective October 1, 2007, by the FDA.
Joint
Meeting of the Nonprescription Drugs and Endocrinologic and Metabolic Drugs
Advisory Committees
December
13, 2007
Thomas
Pickering, M.D.
- 18 U.S.C.
208 waiver (pdf)
- 712 (c)
(2) (B) waiver (pdf)
- Acknowledgement
and consent (pdf)
Page updated:
November 19, 2007
|
|